Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.

导出 OA

翻译打印收藏纠错

第一作者： Karen,Kelly

第一单位： Department of Internal Medicine, University of California-Davis Comprehensive Cancer Center, Sacramento, California.

作者： Karen,Kelly ^[1] ; Jeffrey R,Infante ^[2] ; Matthew H,Taylor ^[3] ; Manish R,Patel ^[4] ; Deborah J,Wong ^[5] ; Nicholas,Iannotti ^[6] ; Janice M,Mehnert ^[7] ; Anja H,Loos ^[8] ; Helga,Koch ^[8] ; Isabell,Speit ^[8] ; James L,Gulley ^[9]

作者单位： Department of Internal Medicine, University of California-Davis Comprehensive Cancer Center, Sacramento, California. ^[1] Sarah Cannon Research Institute/Tennessee Oncology, PLLC, North Nashville, Tennessee. ^[2] Oregon Health and Science University Knight Cancer Institute, Portland, Oregon. ^[3] Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida. ^[4] Department of Medicine, University of California at Los Angeles, Los Angeles, California. ^[5] Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida. ^[6] Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. ^[7] Merck KGaA, Darmstadt, Germany. ^[8] Genitourinary Malignancies Branch, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. ^[9]

关键词 JAVELIN avelumab immunotherapy programmed death-ligand 1 (PD-L1)safety